← Back to Search

Conversation Therapy for Aphasia

N/A
Recruiting
Led By Elizabeth Hoover, PhD
Research Sponsored by Boston University Charles River Campus
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical diagnosis of aphasia
Participants with severe aphasia (Cycle 2)
Must not have
No history of neurological disease (other than stroke)
No current serious medical illness (e.g., cancer)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and up to 12 weeks after baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the efficacy of group conversation treatment for people with aphasia, looking at factors such as group size and composition, and severity of aphasia.

Who is the study for?
This trial is for English-speaking adults with aphasia, a language disorder typically caused by stroke. They must be at least 6 months post-stroke and have enough understanding to join in conversations. The study includes all severity levels of aphasia but excludes those with other neurological diseases, developmental disabilities, or serious illnesses like cancer.
What is being tested?
The study tests group conversation treatment's effectiveness on communication skills in people with aphasia. It examines how different group sizes (2 vs. 6-8 people) and compositions (similar vs. different types of aphasia), as well as the severity of aphasia, impact the treatment outcome.
What are the potential side effects?
Since this is a non-medical intervention focusing on speech therapy through conversation practice, there are no direct medical side effects expected from participating in this trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with difficulty in speaking or understanding language.
Select...
I have severe difficulty speaking or understanding speech.
Select...
I am a native English speaker.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had any neurological diseases, except for a stroke.
Select...
I do not have any serious illnesses right now.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and up to 12 weeks after baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and up to 12 weeks after baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Scores on Aphasia Communication Outcome Measure from Pre- to Post- Treatment
Change in Scores on Aphasia Communication Outcome Measure from Pre-Treatment to One month Post-Treatment
Secondary study objectives
Aphasia Tests
Aphasia Tests

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Experimental: Group compositionExperimental Treatment1 Intervention
Outcomes will be measured for individuals who participate in homogeneous compared to heterogeneous groups (6-8 people with aphasia), based on aphasia severity (severe vs. mild-moderate aphasia).
Group II: Experimental: Group Size x Aphasia SeverityExperimental Treatment1 Intervention
Outcomes will be measured for individuals who participate in large group (6-8 group members) compared to dyads (2 group members), and whether this relationship differs as a function of aphasia severity (severe vs. mild-moderate aphasia).
Group III: Treatment efficacy: Delayed Control GroupActive Control1 Intervention
Treatment cycle 1 only.

Find a Location

Who is running the clinical trial?

Boston University Charles River CampusLead Sponsor
119 Previous Clinical Trials
13,137 Total Patients Enrolled
Temple UniversityOTHER
315 Previous Clinical Trials
88,824 Total Patients Enrolled
Adler Aphasia CenterUNKNOWN

Media Library

Conversation Treatment for Aphasia Clinical Trial Eligibility Overview. Trial Name: NCT05113160 — N/A
Acquired Aphasia Research Study Groups: Treatment efficacy: Delayed Control Group, Experimental: Group Size x Aphasia Severity, Experimental: Group composition
Acquired Aphasia Clinical Trial 2023: Conversation Treatment for Aphasia Highlights & Side Effects. Trial Name: NCT05113160 — N/A
Conversation Treatment for Aphasia 2023 Treatment Timeline for Medical Study. Trial Name: NCT05113160 — N/A
~50 spots leftby Dec 2025